PB2099: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-1607, A FIRST-IN-CLASS ORAL CBL-B INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES INCLUDING RICHTER TRANSFORMATION DLBCL. (23rd June 2022) - Sharp, A.; Williams, A.; Blagden, S.; Plummer, R.; Hochhauser, D.; Krebs, M. G.; Pacey, S.; Evans, J.; Whelan, S.; Nandakumar, S.; Rogers, S.; Jameson, K. L.; et al.